Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6605814rdf:typepubmed:Citationlld:pubmed
pubmed-article:6605814lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:6605814lifeskim:mentionsumls-concept:C0005684lld:lifeskim
pubmed-article:6605814lifeskim:mentionsumls-concept:C0021917lld:lifeskim
pubmed-article:6605814lifeskim:mentionsumls-concept:C0085752lld:lifeskim
pubmed-article:6605814pubmed:dateCreated1984-1-27lld:pubmed
pubmed-article:6605814pubmed:abstractTextIntravesical Adriamycin instillation was used in 10 patients with transitional cell carcinoma of the bladder as postoperative prophylactic treatment against recurrence. The protocol for bladder instillation was 20 mg/10 ml of Adriamycin twice weekly for a total of eight doses. One patient developed recurrence in 3 months and three, in 6 months. The main local side-effects were frequency and dysuria which occurred in four cases. Leukopenia and increased SGOT and SGPT values each occurred in one case. No cases of cardiotoxicity, fibrosis, or atrophy of the bladder mucosa were found. Further studies are necessary to achieve the best possible results.lld:pubmed
pubmed-article:6605814pubmed:languageenglld:pubmed
pubmed-article:6605814pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6605814pubmed:citationSubsetIMlld:pubmed
pubmed-article:6605814pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6605814pubmed:statusMEDLINElld:pubmed
pubmed-article:6605814pubmed:issn0344-5704lld:pubmed
pubmed-article:6605814pubmed:authorpubmed-author:HuangC HCHlld:pubmed
pubmed-article:6605814pubmed:authorpubmed-author:ChiangC PCPlld:pubmed
pubmed-article:6605814pubmed:issnTypePrintlld:pubmed
pubmed-article:6605814pubmed:volume11 Suppllld:pubmed
pubmed-article:6605814pubmed:ownerNLMlld:pubmed
pubmed-article:6605814pubmed:authorsCompleteYlld:pubmed
pubmed-article:6605814pubmed:paginationS91-3lld:pubmed
pubmed-article:6605814pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:meshHeadingpubmed-meshheading:6605814-...lld:pubmed
pubmed-article:6605814pubmed:year1983lld:pubmed
pubmed-article:6605814pubmed:articleTitleBladder instillation of adriamycin in the treatment of bladder cancer.lld:pubmed
pubmed-article:6605814pubmed:publicationTypeJournal Articlelld:pubmed